Attorney's Docket No.: 09011-002003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#4

Applicant : Jens Chr. Jensenius et al.
Serial No. : 09/874,238
Filed : June 4, 2001
Title : MASP-2 COMPLEMENT-FIXING ENZYME, AND USES FOR IT

Art Unit : 1632
Examiner : Unknown

Commissioner for Patents
Washington, D.C. 20231

PRELMINARY AMENDMENT

In response to the communication dated July 3, 2001 (copy enclosed), applicants submit herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, applicants submit an initial Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(f).

Applicants respectfully request entry of the paper copy and computer readable copy of the Sequence Listing filed herewith for the instant application. Furthermore, applicants request entry of the following amendments.

In the specification:

Insert the paper copy of the Sequence Listing filed herewith following the Oath/Declaration.

Replace the paragraph beginning at page 15, line 4, with the following rewritten paragraph:

--Figure 2 shows the sequence alignment[21] of the amino acid sequences of MASP-2 (clone phl-4; amino acid residues 16-686 of SEQ ID NO:2), MASP-1[17,22] (SEQ ID NO:6), C1r[23,24] (SEQ ID NO:7) and C1s[25,26] (SEQ ID NO:8).--

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231

1/3/02
Date of Deposit

Signature

NERISSA M. PARISI
Typed or Printed Name of Person Signing Certificate

Replace the paragraph beginning at page 15, line 14, with the following rewritten paragraph:

--Figure 6 shows the cDNA sequence and deduced amino acid sequence of MASP-2 (SEQ ID NOs:3 and 2, respectively).--

Replace the paragraph beginning at page 46, line 10, with the following rewritten paragraph:

--The liver is the primary site of synthesis of C1r, C1s, and MASP-1. Thus, RNA from liver was used as template for RT-PCR with primers deduced from the obtained peptide sequences. First strand synthesis of cDNA was carried out with 1.3 ìg human liver RNA using a First-Strand cDNA Synthesis Kit (Pharmacia). PCR was performed on this cDNA using degenerate sense and antisense primers derived from the amino acid sequences EYANDQER (SEQ ID NO:4) and KPFTGFEA (SEQ ID NO:5), respectively. The PCR program consisted of 1 cycle with annealing at 50EC; 1 cycle with annealing at 55EC, and 33 cycles with annealing at 60EC. The resulting 300 bp PCR product was cloned into the *E. coli* plasmid pCRII using the TA-cloning kit (InVitrogen) and the nucleotide sequence of the insert was determined.--

REMARKS

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert the paper copy of the Sequence Listing and sequence identifiers in the specification. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 1/3/02

John W. Freeman, Esq.
Reg. No. 29,066

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20310743.doc

"Version With Markings to Show Changes Made"

In the specification:

Paragraph beginning at page 15, line 4, has been amended as follows:

Figure 2 shows the sequence alignment[21] of the amino acid sequences of MASP-2 (clone phl-4; amino acid residues 16-686 of SEQ ID NO:2), MASP-1[17,22] (SEQ ID NO:6), C1r[23,24] (SEQ ID NO:7) and C1s[25,26] (SEQ ID NO:8).

Paragraph beginning at page 15, line 14, has been amended as follows:

Figure 6 shows the cDNA sequence and deduced amino acid sequence of MASP-2 (SEQ ID NOs:3 and 2, respectively).

Paragraph beginning at page 46, line 10, has been amended as follows:

The liver is the primary site of synthesis of C1r, C1s, and MASP-1. Thus, RNA from liver was used as template for RT-PCR with primers deduced from the obtained peptide sequences. First strand synthesis of cDNA was carried out with 1.3 ìg human liver RNA using a First-Strand cDNA Synthesis Kit (Pharmacia). PCR was performed on this cDNA using degenerate sense and antisense primers derived from the amino acid sequences EYANDQER (SEQ ID NO:4) and KPFTGFEA (SEQ ID NO:5), respectively. The PCR program consisted of 1 cycle with annealing at 50EC; 1 cycle with annealing at 55EC, and 33 cycles with annealing at 60EC. The resulting 300 bp PCR product was cloned into the *E. coli* plasmid pCRII using the TA-cloning kit (InVitrogen) and the nucleotide sequence of the insert was determined.